FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 351 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Check Out An All New GreaterGood.Com And Our Renewed Commitment To... September 30, 2019 Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 Load more HOT NEWS COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice
